Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. by Gisondi P et al.
Metabolic abnormalities associated with initiation of systemic 
treatment for psoriasis: evidence from the Italian Psocare Registry. 
Gisondi P, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Girolomoni G, Naldi L, 
Monfrecola G, Psocare Study Group. 
 
Abstract 
OBJECTIVE: 
To evaluate variations in laboratory parameters and diagnoses of selected clinical conditions up to 16 weeks 
after starting a new systemic psoriasis treatment for Psocare Registry enrollees. 
DESIGN: 
Prospective cohort study. 
SETTING: 
Italian public referral centres for psoriasis treatment. 
PATIENTS: 
First-time recipients (n = 10,539) of continuous systemic psoriasis treatment for at least 16 weeks. 
MAIN OUTCOME MEASURE: 
Mean variations in (weeks 8 and 16) and proportions of patients reaching a clinically meaningful increase in 
serum levels (week 16) of total and low-density lipoprotein cholesterol, triglycerides, aspartate amino 
transferase, alanine amino transferase and creatinine, as well as week-16 cumulative incidences of new 
diagnoses of diabetes mellitus and arterial hypertension. 
RESULTS: 
Mean cholesterol and triglyceride levels significantly increased in patients treated with acitretin or 
cyclosporine. Mean triglyceride levels also increased in efalizumab- and etanercept-treated patients. Mean 
transaminase values increased in methotrexate-treated patients, and mean aspartate amino transferase 
levels increased in infliximab-treated patients. The average serum creatinine value increased in 
cyclosporine-treated patients. Acitretin and cyclosporine were associated with risk of hypercholesterolaemia 
(odds ratios 1.51 and 1.34) and acitretin with risk of hypertriglyceridaemia (odds ratio 1.43). Methotrexate 
and infliximab were associated with risk of more than doubling the upper normal aspartate amino transferase 
(odds ratios 2.06 and 1.87) and alanine amino transferase (odds ratios 2.38 and 1.74) values. The relative 
risk of developing arterial hypertension and diabetes was increased for patients receiving cyclosporine (odds 
ratios 3.31 and 2.88). 
CONCLUSION: 
Systemic treatments for psoriasis resulted in heterogeneous effects on the parameters analysed. 
 
